Sarepta Therapeutics (SRPT) reported $611.09 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 68.4%. EPS of $2.02 for the same period compares to $0.07 a ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

U.S. stocks appear set for a positive opening on Thursday as President Donald Trump’s deadline for reciprocal tariffs kicked in from midnight Thursday. In a post on Truth Social, President Trump ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the Cambridge, ...

National shareholders rights firm Hagens Berman continues to investigate the lawsuit's legal claims and urges Sarepta investors who suffered substantial losses to submit your losses now . The firm ...

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

THE LAWSUIT: A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...